Who is 188 com

Applications lacking the appropriate required reference letters will not be reviewed. This is a separate process from submitting an application electronically. See Part 1. Section III. Part I. Overview Information contains information about Key Dates and Times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.

When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day. Organizations must submit applications to Grants. NIH and Grants. Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission.

This initiative is not subject to intergovernmental review. Paper applications will not be accepted. Applicants must complete all required registrations before the application due date. Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply — Application Guide.

If you encounter a system issue beyond your control that threatens your ability to complete the submission process on-time, you must follow the Dealing with System Issues guidance. See more tips for avoiding common errors. Upon receipt, applications will be evaluated for completeness and compliance with application instructions by the Center for Scientific Review, NIH.

Applications that are incomplete or non-compliant will not be reviewed. Applicants are required to follow the instructions for post-submission materials, as described in the policy. Any instructions provided here are in addition to the instructions in the p olicy. Only the review criteria described below will be considered in the review process.

For this particular announcement, note the following : Reviewers should evaluate the candidate's potential for obtaining a tenure-track or equivalent faculty position and developing an independent research program that will make important contributions to the field. Reviewers should consider in their evaluation the likely value of the proposed K99 phase research and career development in facilitating transition to research independence, and the feasibility of the proposed research project as a vehicle for developing a successful, independent research program after transition to the R00 award phase.

Reviewers will consider each of the review criteria below in the determination of scientific merit, and give a separate score for each. An application does not need to be strong in all categories to be judged likely to have major scientific impact. Mentor s , Co-Mentor s , Consultant s , Collaborator s. As applicable for the project proposed, reviewers will evaluate the following additional items while determining scientific and technical merit, and in providing an overall impact score, but will not give separate scores for these items.

For research that involves human subjects but does not involve one of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate the justification for involvement of human subjects and the proposed protections from research risk relating to their participation according to the following five review criteria: 1 risk to subjects, 2 adequacy of protection against risks, 3 potential benefits to the subjects and others, 4 importance of the knowledge to be gained, and 5 data and safety monitoring for clinical trials.

For research that involves human subjects and meets the criteria for one or more of the categories of research that are exempt under 45 CFR Part 46, the committee will evaluate: 1 the justification for the exemption, 2 human subjects involvement and characteristics, and 3 sources of materials. For additional information on review of the Human Subjects section, please refer to the Guidelines for the Review of Human Subjects.

For additional information on review of the Inclusion section, please refer to the Guidelines for the Review of Inclusion in Clinical Research. The committee will evaluate the involvement of live vertebrate animals as part of the scientific assessment according to the following criteria: 1 description of proposed procedures involving animals, including species, strains, ages, sex, and total number to be used; 2 justifications for the use of animals versus alternative models and for the appropriateness of the species proposed; 3 interventions to minimize discomfort, distress, pain and injury; and 4 justification for euthanasia method if NOT consistent with the AVMA Guidelines for the Euthanasia of Animals.

Reviewers will assess the use of chimpanzees as they would any other application proposing the use of vertebrate animals. For additional information on review of the Vertebrate Animals section, please refer to the Worksheet for Review of the Vertebrate Animal Section. For Resubmissions, the committee will evaluate the application as now presented, taking into consideration the responses to comments from the previous scientific review group and changes made to the project. For Revisions, the committee will consider the appropriateness of the proposed expansion of the scope of the project.

If the Revision application relates to a specific line of investigation presented in the original application that was not recommended for approval by the committee, then the committee will consider whether the responses to comments from the previous scientific review group are adequate and whether substantial changes are clearly evident. As applicable for the project proposed, reviewers will consider each of the following items, but will not give scores for these items, and should not consider them in providing an overall impact score.

Reviewers will assess the information provided in this section of the application, including 1 the Select Agent s to be used in the proposed research, 2 the registration status of all entities where Select Agent s will be used, 3 the procedures that will be used to monitor possession use and transfer of Select Agent s , and 4 plans for appropriate biosafety, biocontainment, and security of the Select Agent s.

Reviewers will consider whether the budget and the requested period of support are fully justified and reasonable in relation to the proposed research. Applications will be evaluated for scientific and technical merit by an appropriate Scientific Review Group s , in accordance with NIH peer review policy and procedures , using the stated review criteria. Applications will compete for available funds with all other recommended applications.

Following initial peer review, recommended applications will receive a second level of review by the appropriate national Advisory Council or Board. The following will be considered in making funding decisions:. Refer to Part 1 for dates for peer review, advisory council review, and earliest start date.

A formal notification in the form of a Notice of Award NoA will be provided to the applicant organization for successful applications. Awardees must comply with any funding restrictions described in Section IV. Funding Restrictions. Selection of an application for award is not an authorization to begin performance.

Any costs incurred before receipt of the NoA are at the recipient's risk. These costs may be reimbursed only to the extent considered allowable pre-award costs.

This includes any recent legislation and policy applicable to awards that is highlighted on this website. Recipients of federal financial assistance FFA from HHS must administer their programs in compliance with federal civil rights laws that prohibit discrimination on the basis of race, color, national origin, disability, age and, in some circumstances, religion, conscience, and sex. This includes ensuring programs are accessible to persons with limited English proficiency.

Thus, criteria in research protocols that target or exclude certain populations are warranted where nondiscriminatory justifications establish that such criteria are appropriate with respect to the health or safety of the subjects, the scientific study design, or the purpose of the research.

An applicant, at its option, may review information in the designated integrity and performance systems accessible through FAPIIS and comment on any information about itself that a Federal agency previously entered and is currently in FAPIIS. ICs may, at their discretion, make exceptions to this time limitation when individuals have been invited for faculty job interviews but final decisions have not yet been made by the potential R00 institution or, rarely, because of unusual, extenuating circumstances.

To activate the independent phase of the grant, individuals must have been offered and accepted a tenure-track, full-time assistant professor position or equivalent by the end of the K99 project period. An eligible R00 institution will have appropriate infrastructure to support the proposed research program and a history of external research funding.

However, should the individual accept such a position in the IRP, the independent phase of the award will not be activated. PIs are encouraged to discuss job offers at for-profit organizations with NIH Program staff well in advance of accepting such an offer. To avoid potential problems in activating the independent phase, applicants are strongly encouraged to contact their NIH program official as soon as plans to apply for and assume an independent position develop, and not later than 6 months prior to the termination of the K99 phase of the award.

At that time, individuals should discuss plans for transition to, and application for, the R00 phase with their NIH program official. The application for the R00 phase of the award should be submitted no later than 2 months prior to the proposed activation date of the R00 award by the R00 phase grantee organization. The independent phase institution will submit an application on behalf of the candidate for the R00 award using the PHS Application.

The R00 application must include:. These materials should be sent directly to the awarding Institute or Center IC. The R00 application will be evaluated by extramural program staff of the awarding component for completeness and appropriateness to the program. Two additional documents are included with the R00 application. If not already provided, the final evaluation statement by the K99 phase mentor must be provided. The start-up package and other institutional support must be described in detail and must be comparable to that given to other faculty recently hired into tenure-track or equivalent faculty positions.

Institutions must provide a startup and salary package equivalent to that provided to a newly hired faculty member who does not have a grant; R00 funds may not be used to offset the typical startup package or to offset the usual institutional commitment to provide salary for tenure-track or equivalent assistant professors who are hired without grant support.

Consequently, teaching, clinical duties and other non-research activities should be minimal during the R00 award period. NIH staff may review start-up packages and other commitments between the institution and candidate prior to activating the independent phase of the award. NIH will not activate the independent phase if the institutional commitment is deemed inadequate.

Applicants who are approved to transition will receive a Notice of Award reflecting the new R00 grant mechanism, the dollar amount, and the new recipient organization if applicable. Consequently, a requirement for activation of the R00 phase is successful completion of this transition. You do not stay angry forever but delight to show mercy. New Living Translation Where is another God like you, who pardons the guilt of the remnant, overlooking the sins of his special people?

You will not stay angry with your people forever, because you delight in showing unfailing love. English Standard Version Who is a God like you, pardoning iniquity and passing over transgression for the remnant of his inheritance? He does not retain his anger forever, because he delights in steadfast love. Berean Study Bible Who is a God like You, who pardons iniquity and passes over the transgression of the remnant of His inheritance—who does not retain His anger forever, because He delights in loving devotion?

King James Bible Who is a God like unto thee, that pardoneth iniquity, and passeth by the transgression of the remnant of his heritage? He does not retain His anger forever, Because He delights in mercy. He does not retain His anger forever, Because He delights in unchanging love. Amplified Bible Who is a God like You, who forgives wickedness And passes over the rebellious acts of the remnant of His possession?

He does not retain His anger forever, Because He [constantly] delights in mercy and lovingkindness. Christian Standard Bible Who is a God like you, forgiving iniquity and passing over rebellion for the remnant of his inheritance? He does not hold on to his anger forever because he delights in faithful love. Holman Christian Standard Bible Who is a God like You, removing iniquity and passing over rebellion for the remnant of His inheritance?

He does not hold on to His anger forever, because He delights in faithful love. American Standard Version Who is a God like unto thee, that pardoneth iniquity, and passeth over the transgression of the remnant of his heritage? Aramaic Bible in Plain English There is no God like you who forgives evil and passes over the sin of the remainder of his inheritance, and you do not hold a grudge to eternity because you have chosen grace Brenton Septuagint Translation Who is a God like thee, cancelling iniquities, and passing over the sins of the remnant of his inheritance?

Contemporary English Version Our God, no one is like you. We are all that is left of your chosen people, and you freely forgive our sin and guilt.

You don't stay angry forever; you're glad to have pity Douay-Rheims Bible Who is a God like to thee, who takest away iniquity, and passest by the sin of the remnant of thy inheritance? English Revised Version Who is a God like unto thee, that pardoneth iniquity, and passeth by the transgression of the remnant of his heritage?

You do not stay angry forever, but you take pleasure in showing us your constant love. Overall, it serves as an important component for the smooth functioning of internet. When a user types the name of a site in a browser, the DNS finds the corresponding IP address for it and any other data required to get the desired network connection.

So a Domain Name System is actually a friendly way of naming the web servers or the web pages. It defines addresses to them. They work very similar to an international phone number and give servers an easy to remember and easy to spell address. On the other hand, they also hide the IP addresses that are technical and are not very useful to the viewer as well.

Apart from all that is mentioned above, the domain system is also responsible for assigning domain names and mapping those names to the internet resources by providing name servers to every particular domain.

The internet maintains two different spaces for names; one is for domain name hierarchy while the second one is for IP address.

It is also important to know here that the domain name system provides the translation services to and fro on the internet. How to read Domain names? The domain names are always organized from right to left as is the case in any name the family names to the right and the personal names to the left. These descriptors are actually called 'Domains'. The TLD or the Top Level Domain, also called the parent domain is mentioned to the far right of a domain name; the mid-level domains are obviously in the middle while the machine name is to the far left.

It is often "www". The different levels of domains are separated by dots or periods. Some facts about the Domain Name Systems.